Bullish Options Sentiment in Allergan (AGN) Targets Upside Into 2018 -Susquehanna
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Allergan (AGN) Receives Approval for Ozurdex in China for Treatment of RVO
October 30, 2017 8:01 AM EDTAllergan plc (NYSE: AGN) announced today that it has received an Imported Drugs License (IDL) from the Chinese Food and Drug Administration (CFDA) to market Ozurdex® (dexamethasone intravitreal implant 0.7 mg) for the treatment of adult patients with macular edema following either Branch Retinal Vein Occlusion (BRVO) or Central Retinal Vein Occlusion (CRVO).
Ozurdex is the first approved intravitreal injection for RVO in China. Retinal vein occlusion (RVO) is the second most common type of retinal vascular disorder after diabetic retinal disease and one of the most common causes of sudden, painless,... More
Allergan (AGN) Declares $0.70 Quarterly Dividend, Approves $0.72 Quarterly Dividend for 2018
October 27, 2017 8:03 AM EDTAllergan (NYSE: AGN) declared a quarterly dividend of $0.70 per share, or $2.8 annualized.
The dividend will be payable on December 15, 2017, to stockholders of record on November 17, 2017, with an ex-dividend date of November 16, 2017.
The annual yield on the dividend is 1.6 percent.
The... More
